IBEX LTD (IBEX) Stock Fundamental Analysis

NASDAQ:IBEX • BMG4690M1010

29.55 USD
0 (0%)
At close: Feb 20, 2026
29.55 USD
0 (0%)
After Hours: 2/20/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to IBEX. IBEX was compared to 87 industry peers in the IT Services industry. IBEX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. An interesting combination arises when we look at growth and value: IBEX is growing strongly while it also seems undervalued. These ratings would make IBEX suitable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • IBEX had positive earnings in the past year.
  • IBEX had a positive operating cash flow in the past year.
  • IBEX had positive earnings in each of the past 5 years.
  • IBEX had a positive operating cash flow in each of the past 5 years.
IBEX Yearly Net Income VS EBIT VS OCF VS FCFIBEX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M

1.2 Ratios

  • IBEX's Return On Assets of 14.98% is amongst the best of the industry. IBEX outperforms 94.25% of its industry peers.
  • Looking at the Return On Equity, with a value of 28.69%, IBEX belongs to the top of the industry, outperforming 89.66% of the companies in the same industry.
  • The Return On Invested Capital of IBEX (21.96%) is better than 95.40% of its industry peers.
Industry RankSector Rank
ROA 14.98%
ROE 28.69%
ROIC 21.96%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IBEX Yearly ROA, ROE, ROICIBEX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100

1.3 Margins

  • IBEX has a Profit Margin of 7.35%. This is in the better half of the industry: IBEX outperforms 74.71% of its industry peers.
  • IBEX's Profit Margin has improved in the last couple of years.
  • IBEX has a Operating Margin of 9.38%. This is in the better half of the industry: IBEX outperforms 66.67% of its industry peers.
  • In the last couple of years the Operating Margin of IBEX has grown nicely.
  • IBEX has a Gross Margin (30.36%) which is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of IBEX has remained more or less at the same level.
Industry RankSector Rank
OM 9.38%
PM (TTM) 7.35%
GM 30.36%
OM growth 3Y27.75%
OM growth 5Y12.6%
PM growth 3Y14.82%
PM growth 5Y27.95%
GM growth 3Y0.55%
GM growth 5YN/A
IBEX Yearly Profit, Operating, Gross MarginsIBEX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • IBEX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • There is no outstanding debt for IBEX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IBEX Yearly Shares OutstandingIBEX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
IBEX Yearly Total Debt VS Total AssetsIBEX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • An Altman-Z score of 4.88 indicates that IBEX is not in any danger for bankruptcy at the moment.
  • IBEX's Altman-Z score of 4.88 is amongst the best of the industry. IBEX outperforms 80.46% of its industry peers.
  • IBEX has a debt to FCF ratio of 0.05. This is a very positive value and a sign of high solvency as it would only need 0.05 years to pay back of all of its debts.
  • The Debt to FCF ratio of IBEX (0.05) is better than 91.95% of its industry peers.
  • IBEX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • IBEX's Debt to Equity ratio of 0.00 is amongst the best of the industry. IBEX outperforms 83.91% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.05
Altman-Z 4.88
ROIC/WACC2.24
WACC9.82%
IBEX Yearly LT Debt VS Equity VS FCFIBEX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 1.83 indicates that IBEX should not have too much problems paying its short term obligations.
  • IBEX's Current ratio of 1.83 is in line compared to the rest of the industry. IBEX outperforms 54.02% of its industry peers.
  • IBEX has a Quick Ratio of 1.83. This is a normal value and indicates that IBEX is financially healthy and should not expect problems in meeting its short term obligations.
  • IBEX has a Quick ratio (1.83) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.83
Quick Ratio 1.83
IBEX Yearly Current Assets VS Current LiabilitesIBEX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • IBEX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.77%, which is quite impressive.
  • The Earnings Per Share has been growing by 41.04% on average over the past years. This is a very strong growth
  • Looking at the last year, IBEX shows a quite strong growth in Revenue. The Revenue has grown by 15.63% in the last year.
  • IBEX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.62% yearly.
EPS 1Y (TTM)44.77%
EPS 3Y28.16%
EPS 5Y41.04%
EPS Q2Q%47.46%
Revenue 1Y (TTM)15.63%
Revenue growth 3Y4.24%
Revenue growth 5Y6.62%
Sales Q2Q%16.73%

3.2 Future

  • Based on estimates for the next years, IBEX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.72% on average per year.
  • Based on estimates for the next years, IBEX will show a quite strong growth in Revenue. The Revenue will grow by 9.67% on average per year.
EPS Next Y22.95%
EPS Next 2Y13.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year13.82%
Revenue Next 2Y9.67%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IBEX Yearly Revenue VS EstimatesIBEX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
IBEX Yearly EPS VS EstimatesIBEX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 8.54, which indicates a very decent valuation of IBEX.
  • Based on the Price/Earnings ratio, IBEX is valued cheaper than 88.51% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.99. IBEX is valued rather cheaply when compared to this.
  • The Price/Forward Earnings ratio is 8.16, which indicates a very decent valuation of IBEX.
  • Based on the Price/Forward Earnings ratio, IBEX is valued cheaply inside the industry as 89.66% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.06, IBEX is valued rather cheaply.
Industry RankSector Rank
PE 8.54
Fwd PE 8.16
IBEX Price Earnings VS Forward Price EarningsIBEX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • IBEX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. IBEX is cheaper than 93.10% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, IBEX is valued a bit cheaper than the industry average as 72.41% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 13.53
EV/EBITDA 5.14
IBEX Per share dataIBEX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of IBEX may justify a higher PE ratio.
  • A more expensive valuation may be justified as IBEX's earnings are expected to grow with 13.72% in the coming years.
PEG (NY)0.37
PEG (5Y)0.21
EPS Next 2Y13.72%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • IBEX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IBEX LTD

NASDAQ:IBEX (2/20/2026, 8:00:01 PM)

After market: 29.55 0 (0%)

29.55

0 (0%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustryIT Services
Earnings (Last)02-05
Earnings (Next)05-06
Inst Owners94.08%
Inst Owner Change3.56%
Ins Owners2.8%
Ins Owner Change14.03%
Market Cap396.27M
Revenue(TTM)603.27M
Net Income(TTM)44.32M
Analysts45.71
Price Target41.82 (41.52%)
Short Float %0.8%
Short Ratio0.82
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.35%
Min EPS beat(2)8.65%
Max EPS beat(2)20.05%
EPS beat(4)4
Avg EPS beat(4)15.36%
Min EPS beat(4)8.65%
Max EPS beat(4)21.85%
EPS beat(8)8
Avg EPS beat(8)15.45%
EPS beat(12)10
Avg EPS beat(12)11.12%
EPS beat(16)13
Avg EPS beat(16)15.27%
Revenue beat(2)2
Avg Revenue beat(2)3.02%
Min Revenue beat(2)2.5%
Max Revenue beat(2)3.54%
Revenue beat(4)4
Avg Revenue beat(4)4.92%
Min Revenue beat(4)2.5%
Max Revenue beat(4)8.52%
Revenue beat(8)6
Avg Revenue beat(8)2.69%
Revenue beat(12)6
Avg Revenue beat(12)0.39%
Revenue beat(16)7
Avg Revenue beat(16)-0.19%
PT rev (1m)0%
PT rev (3m)6.49%
EPS NQ rev (1m)-2.2%
EPS NQ rev (3m)-2.2%
EPS NY rev (1m)0%
EPS NY rev (3m)5.47%
Revenue NQ rev (1m)0.91%
Revenue NQ rev (3m)1.14%
Revenue NY rev (1m)0.89%
Revenue NY rev (3m)2.72%
Valuation
Industry RankSector Rank
PE 8.54
Fwd PE 8.16
P/S 0.66
P/FCF 13.53
P/OCF 6.71
P/B 2.56
P/tB 2.78
EV/EBITDA 5.14
EPS(TTM)3.46
EY11.71%
EPS(NY)3.62
Fwd EY12.25%
FCF(TTM)2.18
FCFY7.39%
OCF(TTM)4.41
OCFY14.91%
SpS44.99
BVpS11.52
TBVpS10.64
PEG (NY)0.37
PEG (5Y)0.21
Graham Number29.95
Profitability
Industry RankSector Rank
ROA 14.98%
ROE 28.69%
ROCE 27.05%
ROIC 21.96%
ROICexc 23.71%
ROICexgc 25.25%
OM 9.38%
PM (TTM) 7.35%
GM 30.36%
FCFM 4.85%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y27.75%
OM growth 5Y12.6%
PM growth 3Y14.82%
PM growth 5Y27.95%
GM growth 3Y0.55%
GM growth 5YN/A
F-Score8
Asset Turnover2.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.05
Debt/EBITDA 0.01
Cap/Depr 168.3%
Cap/Sales 4.94%
Interest Coverage 42.98
Cash Conversion 79.5%
Profit Quality 66.06%
Current Ratio 1.83
Quick Ratio 1.83
Altman-Z 4.88
F-Score8
WACC9.82%
ROIC/WACC2.24
Cap/Depr(3y)83.97%
Cap/Depr(5y)108.52%
Cap/Sales(3y)2.89%
Cap/Sales(5y)3.72%
Profit Quality(3y)75.63%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.77%
EPS 3Y28.16%
EPS 5Y41.04%
EPS Q2Q%47.46%
EPS Next Y22.95%
EPS Next 2Y13.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)15.63%
Revenue growth 3Y4.24%
Revenue growth 5Y6.62%
Sales Q2Q%16.73%
Revenue Next Year13.82%
Revenue Next 2Y9.67%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.68%
EBIT growth 3Y33.16%
EBIT growth 5Y20.06%
EBIT Next Year68.46%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y50.53%
FCF growth 3Y24.66%
FCF growth 5Y-10.09%
OCF growth 1Y85.57%
OCF growth 3Y4.51%
OCF growth 5Y-2.46%

IBEX LTD / IBEX FAQ

Can you provide the ChartMill fundamental rating for IBEX LTD?

ChartMill assigns a fundamental rating of 7 / 10 to IBEX.


What is the valuation status for IBEX stock?

ChartMill assigns a valuation rating of 8 / 10 to IBEX LTD (IBEX). This can be considered as Undervalued.


What is the profitability of IBEX stock?

IBEX LTD (IBEX) has a profitability rating of 7 / 10.


What is the valuation of IBEX LTD based on its PE and PB ratios?

The Price/Earnings (PE) ratio for IBEX LTD (IBEX) is 8.54 and the Price/Book (PB) ratio is 2.56.


Is the dividend of IBEX LTD sustainable?

The dividend rating of IBEX LTD (IBEX) is 0 / 10 and the dividend payout ratio is 0%.